The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...

Please provide your email address to receive an email when new articles are posted on . Adbry is approved for moderate to severe atopic dermatitis. The autoinjector delivers a single 300 mg/mL dose.

The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD. The Food and Drug Administration ...

If you have atopic dermatitis, a skin condition commonly known as eczema, prescription creams or other topical medicines and moisturizers are usually enough to manage it. However, if your eczema is ...

A new device for the injection of tralokinumab is one step closer to approval in European Union member states. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Please provide your email address to receive an email when new articles are posted on . Adbry is now available in the U.S. as a 300 mg/2 mL single-dose autoinjector for adults with atopic dermatitis.